Product Images Aripiprazole

This document likely presents the change in total tic score in patients with Tourette's Syndrome over the course of 20 weeks of treatment, utilizing a statistical method known as least-squares mean. The medication ARIP (presumably high and low dosage) is compared to a placebo group. However, without additional context or data, it is difficult to provide further details.*

This is a description for Aripiprazole Oral Solution, which comes in a bottle that has a tamper-evident seal. The solution contains 1mg of aripiprazole per milliliter, and the recommended dosage can be found within the package insert. The bottle should be stored within temperatures of 20-25°C, while excursions are allowed at 15-30°C. After opening, it can be used for six months before being discarded. The solution is distributed by Amneal Pharmaceuticals, LLC and comes with a medication guide enclosed for patients. The net contents of the bottle are 8 with NDC code 65162-893-74.*

This is a description for Aripiprazole Oral Solution, indicated for the treatment of schizophrenia and bipolar I disorder. This solution comes in a tamper-evident bottle containing 150 mL of aqueous solution with a concentration of 1 mg/mL of Aripiprazole USP. The dosing cup is provided along with the package insert to guide on indications and dosage. The bottle should be stored between 20°C to 25°C (68°F to 77°F) with a provision of 15°C to 30°C (59°F to 86°F). Opened bottles can be used up to 6 months but not after the expiration date mentioned on the bottle, which should be discarded accordingly. The distribution of the medication is done by Amneal Pharmaceuticals LLC.*

This text provides a table showing the effect of various drugs on aripiprazole, a medication used to treat certain mental/mood disorders. The table displays fold changes and their associated confidence intervals for aripiprazole's pharmacokinetics when used with different drugs. The drugs are categorized as CYP3AA inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others such as valproate, lithium, and lorazepam. The table also shows the change relative to the drug reference without any interacting drugs.*

The text describes the effects of various drugs on aripiprazole and the fold change in Dehydro-Aripiprazole. Different drugs like inhibitors and inducers of CYP3A4 and CYP2D6 were tested, alongside other drugs such as gastric acid blockers, valproate, lithium, and lorazepam. The concentrations of various drugs were measured (Cmax, AUC) and compared to a reference without any interacting drugs. The results are presented in a graph showing the fold change and 90% CI of Dehydro-Aripiprazole relative to the reference.*

The text appears to be a table showing the effect of Aripiprazole on other drugs with regards to various parameters such as CYP2D6 B, dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The table also includes fold change and 90% CI data for each drug.*

This is a table outlining different special populations and their characteristics. It includes comparisons of poor vs. extensive metabolizers of CYP206, female vs. male genders, ages 18-64 vs. >65 years old, and various degrees of hepatic and renal impairment. Additionally, there are some pharmacokinetic parameters listed (AUC, Ccmax, chist, ohli, ohlk) and information on Arpiprazole Fold Change and 90% CI. The significance or implications of this information is not provided.*

This is a collection of medical data related to pharmacokinetics and pharmacogenetics. Specifically, it includes information regarding the CYP2D6 enzyme, metabolizer status, gender, age, hepatic and renal impairment. There are also measurements related to drug concentration (cmax), area under the curve (AUC), and Dehydro-Aripiprazole Fold Change with 90% confidence interval. However, the meaning and context of the data cannot be inferred from the provided text alone.*

The text seems to be an incomplete chart or figure showing some medication (Aripiprazole) compared to a placebo in a study involving patients experiencing a relapse. Therefore, no useful description can be generated from this text, as it lacks essential information to provide a meaningful summary.*

This seems to be a table that shows the proportion of subjects with relapse in a clinical trial involving a drug called "ARIPIPRAZOLE" compared to a placebo group. It also shows the number of subjects at risk over a period of time in days from randomization. There is not enough information to determine the extent or context of the clinical trial.*